Patents Assigned to Boehringer Ingelheim International GmbH
  • Patent number: 10596120
    Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: March 24, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Masanori Ito, Kenji Egusa, Roman Messerschmid, Peter Schneider
  • Patent number: 10576222
    Abstract: A nebulizer as well as a container and an indicator device for such a nebulizer are proposed. The indicator device is fixedly mounted from the bottom of the container and comprises a piercing element for opening an aeration of the container. The indicator device and its piercing part are preferably actuated by axial movement of the indicator device and container within the nebulizer.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: March 3, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joachim Eicher, Gilbert Wuttke, Alfred Von Schuckmann
  • Patent number: 10576064
    Abstract: The present invention relates to compounds of formula (I) wherein the groups R1 to R3, R7, U, V, W, X, Y, n and q are as defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases and synthetic intermediates.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: March 3, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Weinstabl, Andreas Gollner, Juergen Ramharter, Tobias Wunberg
  • Patent number: 10577336
    Abstract: The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: March 3, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rocco Mazzaferro, Marco Ferrara, Riccardo Giovannini, Iain Lingard, Klaus Rudolf
  • Patent number: 10570118
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, R2, R3, R4 and R5 are defined herein, which are suitable for the treatment of diseases related to Bruton's tyrosine kinase (BTK), and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: February 25, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Todd Bosanac, Joerg Bentzien, Michael Jason Burke, Darren Todd DiSalvo, Wang Mao, Fariba Soleymanzadeh, John A. Westbrook, Zhaoming Xiong
  • Patent number: 10550127
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: February 4, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Holger Wagner, Stefan Peters
  • Patent number: 10550189
    Abstract: The present invention relates to anti-interleukin-36R (anti-IL-36R) binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: February 4, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Su-Ellen Brown, Keith Canada, Lukasz Chlewicki, Michael Howell, Detlev Mennerich, Joseph Robert Woska, Jr.
  • Patent number: 10544177
    Abstract: This invention relates to novel phosphorous ligands useful for organic transformations. Methods of making and using the ligands in organic synthesis are described. The invention also relates to processes for preparing the novel ligands.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: January 28, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jean-Nicolas Desrosiers, Daniel Robert Fandrick, Nizar Haddad, Guisheng Li, Nitinchandra D. Patel, Bo Qu, Sonia Rodriguez, Chris Hugh Senanayake, Joshua Daniel Sieber, Zhulin Tan, Xiao-Jun Wang, Nathan K. Yee, Li Zhang, Yongda Zhang
  • Publication number: 20200024261
    Abstract: The present invention relates to difluoromethyl-phenyl triazoles of general formula (I) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: July 19, 2019
    Publication date: January 23, 2020
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Janus Schreiber Larsen, Florian Binder, Yunhai Cui, Oliver Hucke, Radoslaw Lipinski, Florian Montel, Markus Ostermeier, Alexandre Perera, Stefan Peters
  • Patent number: 10538490
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, including binding to the GPR40 receptor and modulating its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: January 21, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Stefan Peters, Holger Wagner
  • Patent number: 10537590
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and R3 are defined as in claim 1, which have valuable pharmacological properties, particularly are modulators of STING.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: January 21, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thorsten Oost, Sebastian Carotta, Martin Fleck
  • Patent number: 10507241
    Abstract: This invention generally relates to biomarkers useful in the treatment of IL-23 related diseases, in particular inflammatory diseases such as psoriasis. The invention also relates to methods of using the biomarkers disclosed herein, for example in therapies utilizing IL-23 antagonists.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: December 17, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Sudha Visvanathan, Patrick Baum, Oliver Kleiner, Ulrich Kunz
  • Patent number: 10500355
    Abstract: The invention relates to a system composed of an inhaler and a capsule, preferably intended for single use. The capsule contains a preferably powdered pharmaceutical preparation which, for inhalation, is expelled from the capsule through at least one hole. The capsule comprises as capsule elements a capsule cap and a capsule body, at least one of which comprises at least one prefabricated hole. The prefabricated hole in the capsule is sealed off in the transporting state of the system and is open in the usage state. The hole is exposed by actuation of a pulling mechanism. Prior to this the hole is closed off by a capsule receptacle or a film. In one embodiment the capsule may be present in two different states, for example in different insertion positions of the capsule elements. In the first state the prefabricated hole is closed off and in the second it is exposed. Also shown is an inhaler suitable as a disposable product, which is manufactured from thermoformed parts or from blister film.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: December 10, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Holger Holakovsky, Jessica Frentzel-Beyme, Stephen Terence Dunne, Jens Besseler, Claudius Weiler
  • Patent number: 10501440
    Abstract: Disclosed are heteroarylcarboxamides of formula (I), and pharmaceutically acceptable salts thereof, wherein A, T, R1, R2 and R3 are as defined herein. Also disclosed are methods of using these compounds for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: December 10, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Sara Frattini, Iain Lingard, Dieter Wolfgang Hamprecht, Remko Alexander Bakker, Matthias Eckhardt, Andreas Gollner, Joerg P. Hehn, Elke Langkopf, Holger Wagner, Bernd Wellenzohn, Dieter Wiedenmayer
  • Publication number: 20190359701
    Abstract: This invention generally relates to methods for the treatment of respiratory diseases, such as asthma, utilizing anti-IL-23A antibodies.
    Type: Application
    Filed: March 8, 2019
    Publication date: November 28, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Kirsten ARNDT-SCHMITZ, Alix BERTON, Michael Chadham NIVENS, Karsten QUAST, Marco SCHLEPUETZ, Sudha VISVANATHAN
  • Patent number: 10479794
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: November 19, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christoph Hoenke, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Sara Frattini, Riccardo Giovannini, Scott Hobson
  • Patent number: 10450314
    Abstract: The present invention encompasses compounds of formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: October 22, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steven Richard Brunette, Johanna Csengery, Robert Owen Hughes, Xiang Li, Robert Sibley, Michael Robert Turner, Zhaoming Xiong
  • Publication number: 20190313949
    Abstract: A system and a method for detection of a respiratory status, wherein the system comprises a flexible patch being configured to be affixed to the skin of a patient's body, wherein the patch has at least one sensor arrangement for sensing a body activity of the patient's body when the patch is affixed to the skin, and wherein the sensor arrangement is configured to determine and/or output a sensor signal corresponding to said body activity. The system is configured to determine a respiratory airflow indicator based on the sensor signal. Alternatively, or additionally, the system has a re-usable add-on device that is attachable to and detachable from the patch and is adapted to provide energy to and/or receive the sensor signal from the patch.
    Type: Application
    Filed: December 5, 2017
    Publication date: October 17, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Leticia Moreira Goulart ORSATTI, Roberto Slepetys FERREIRA
  • Patent number: 10442795
    Abstract: The present invention relates to processes for preparing the compounds of general formula I, wherein the groups R1 and R3 are defined according to claim 1. Furthermore this inventions relates to intermediates obtained in these processes.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: October 15, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Frank Himmelsbach, Xiao-Jun Wang, Wenjun Tang, Xiufeng Sun, Li Zhang, Dhileepkumar Krishnamurthy, Christopher Hugh Senanayake, Zhengxu Han
  • Publication number: 20190307648
    Abstract: A system and a method for medication adherence management with which a medicament container is held by a holding apparatus, a detector device wirelessly recognizes an opening and closing activity of the medicament container, and a data processing device or control device reads and processes data of the detector device.
    Type: Application
    Filed: October 9, 2017
    Publication date: October 10, 2019
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventor: Holger BARTOS